)
MedinCell (MEDCL) investor relations material
MedinCell Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic growth and business transformation
Entering a transformative two-year period with a shift to growth strategy, focusing on three parallel engines: partnerships (AbbVie), pipeline innovation, and commercialized products (Risperidone LAI/UZEDY®, Olanzapine LAI).
Teva partnership central to commercial execution, leveraging its psychiatry sales force and global reach.
Multiple long-term partnerships and stacked royalty streams underpin future value creation.
Schizophrenia franchise and product performance
UZEDY® (Risperidone LAI) approved in the US (2023), South Korea, and Canada, with strong prescription growth and over 15,000 patients treated.
UZEDY® net sales projected to grow 63% in 2025, reaching $191M, with 2026 outlook at $250–280M.
Analysts forecast UZEDY® peak sales at $1.2B (range $0.6–2.2B), with Medincell earning mid- to high-single digit royalties and up to $105M in milestones.
Real-world data show UZEDY® reduces relapse, inpatient rates, and healthcare costs compared to oral antipsychotics.
UZEDY® protected by US patents through 2042.
Olanzapine LAI development and opportunity
Olanzapine LAI submitted for US and EU approval in 2025, with US launch anticipated in Q4 2026.
Addresses unmet need due to safety constraints of existing LAIs; no valid competitor and no observed PDSS in clinical trials.
Analysts forecast peak sales at $2.0B (range $1.5–2.9B), with similar royalty and milestone structure as UZEDY®.
Patent protection extends to 2044.
- UZEDY® royalties surged 42% and pipeline advanced, with Olanzapine LAI set for Q4 2026 US launch.MEDCL
H2 25/2616 Jun 2026 - Strong sales and pipeline advances set the stage for transformative growth in 2026.MEDCL
Jefferies Global Healthcare Conference 20264 Jun 2026 - Platform innovation, strategic partnerships, and robust IP drive scalable, royalty-based growth.MEDCL
R&D Day 202612 May 2026 - UZEDY launch, AbbVie deal, and clinical progress drive strong financial and pipeline momentum.MEDCL
H2 23/242 Feb 2026 - UZEDY royalties and AbbVie deal drove revenue up 23%, but net loss widened on financial charges.MEDCL
H1 24/2511 Jan 2026 - Strong product launches and partnerships position for profitability and €200M EBITDA by 2030.MEDCL
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025 - 50% revenue growth, UZEDY® expansion, Olanzapine LAI NDA, and strong liquidity.MEDCL
H1 25/2619 Dec 2025 - UZEDY and long-acting olanzapine are set for major growth, driven by clinical and market advances.MEDCL
Evercore ISI 8th Annual HealthCONx Conference3 Dec 2025 - UZEDY's commercial success and expanding LAI pipeline fuel strong growth and future profitability.MEDCL
TD Cowen 45th Annual Healthcare Conference2 Dec 2025
Next MedinCell earnings date
Next MedinCell earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage